If I may suggest a different perspective, 2019 is not the focus at all, but upcoming clinical efficacy and 2016 are DEFINITELY where it's at. A noted, that's when if the clinical sun is shining, the 'Pfizers' and Mutual Fund managers of the world open their wallets and buy, buy. Or as noted, if not, back to our utilities and 'GE's'.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.